{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:41:52Z","timestamp":1791283312225,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.contraception.2013.12.003","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T13:15:51Z","timestamp":1387458951000},"page":"242-252","source":"Crossref","is-referenced-by-count":38,"title":["Gestodene: A review of its pharmacology, potency and tolerability in combined contraceptive preparations"],"prefix":"10.1016","volume":"89","author":[{"given":"Frank Z.","family":"Stanczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David F.","family":"Archer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2013.12.003_bb0005","unstructured":"UN Department of Economic and Social Affairs Population Division. World contraceptive use 2012 [cited Last accessed: 5 December 2012.]."},{"issue":"28\u201329","key":"10.1016\/j.contraception.2013.12.003_bb0010","first-page":"495","article-title":"Hormonal contraception-what kind, when, and for whom?","volume":"108","author":"Wiegratz","year":"2011","journal-title":"Dtsch Arztebl Int"},{"issue":"1A","key":"10.1016\/j.contraception.2013.12.003_bb0015","doi-asserted-by":"crossref","first-page":"104S","DOI":"10.1016\/S0002-9343(99)80067-9","article-title":"The androgenicity of progestins","volume":"98","author":"Darney","year":"1995","journal-title":"Am J Med"},{"issue":"8990","key":"10.1016\/j.contraception.2013.12.003_bb0490","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0140-6736(95)91927-9","article-title":"Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception","volume":"346","year":"1995","journal-title":"Lancet"},{"issue":"8990","key":"10.1016\/j.contraception.2013.12.003_bb0025","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/S0140-6736(95)91929-5","article-title":"Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen","volume":"346","author":"Bloemenkamp","year":"1995","journal-title":"Lancet"},{"issue":"8990","key":"10.1016\/j.contraception.2013.12.003_bb0030","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/S0140-6736(95)91928-7","article-title":"Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components","volume":"346","author":"Jick","year":"1995","journal-title":"Lancet"},{"issue":"7023","key":"10.1016\/j.contraception.2013.12.003_bb0035","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.312.7023.83","article-title":"Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case\u2013control study. Transnational Research Group on Oral Contraceptives and the Health of Young Women","volume":"312","author":"Spitzer","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.contraception.2013.12.003_bb0040","series-title":"Risk issues and crisis management: a casebook of best practice","year":"2005"},{"issue":"6","key":"10.1016\/j.contraception.2013.12.003_bb0045","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/S0029-7844(97)00132-4","article-title":"Third-generation oral contraceptives and thromboembolism risk","volume":"89","author":"Poindexter","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2013.12.003_bb0050","series-title":"Gestodene: A New Direction in Oral Contraception","first-page":"13","article-title":"Pharmacological features of gestodene in laboratory animals and man","author":"Dusterberg","year":"1988"},{"issue":"Suppl. 1","key":"10.1016\/j.contraception.2013.12.003_bb0055","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/13697130500148875","article-title":"Pharmacology of estrogens and progestogens: influence of different routes of administration","volume":"8","author":"Kuhl","year":"2005","journal-title":"Climacteric"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0060","doi-asserted-by":"crossref","first-page":"316","DOI":"10.3109\/09513599909167574","article-title":"The pharmacological profile of a novel norpregnance progestin (trimegestone)","volume":"13","author":"Philibert","year":"1999","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2013.12.003_bb0065","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1210\/er.2012-1008","article-title":"Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects","volume":"34","author":"Stanczyk","year":"2013","journal-title":"Endocr Rev"},{"issue":"3","key":"10.1016\/j.contraception.2013.12.003_bb0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1159\/000298860","article-title":"Efficacy of low-dose oral contraceptives containing levonorgestrel, gestoden and cyproterone acetate","volume":"23","author":"Spona","year":"1987","journal-title":"Gynecol Obstet Invest"},{"key":"10.1016\/j.contraception.2013.12.003_bb0075","series-title":"Progestins and anti-progestins in clinical practice","first-page":"179","article-title":"Progestogens in contraception: third-generation pills","author":"Gaspard","year":"2000"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0080","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1021\/tx00016a015","article-title":"Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene","volume":"3","author":"Guengerich","year":"1990","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0085","doi-asserted-by":"crossref","first-page":"188","DOI":"10.2165\/00003495-199651020-00002","article-title":"Comparative pharmacology of newer progestogens","volume":"51","author":"Kuhl","year":"1996","journal-title":"Drugs"},{"key":"10.1016\/j.contraception.2013.12.003_bb0495","series-title":"Gestodene: development of a new gestodene-containing low-dose oral contraceptive","first-page":"35","article-title":"Pharmacokinetics and biotransformation of gestodene in man","author":"Dusterberg","year":"1987"},{"issue":"4 Pt 2","key":"10.1016\/j.contraception.2013.12.003_bb0095","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/0002-9378(90)91358-J","article-title":"Pharmacokinetics of gestodene and ethinyl estradiol after oral administration of a monophasic contraceptive","volume":"163","author":"Tauber","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0010-7824(89)90053-X","article-title":"Single dose pharmacokinetics of gestodene in women after intravenous and oral administration","volume":"40","author":"Tauber","year":"1989","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0105","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0010-7824(91)90069-R","article-title":"The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel","volume":"43","author":"Orme","year":"1991","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0110","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/0010-7824(88)90088-1","article-title":"Alterations in the serum levels of gestodene and SHBG during 12cycles of treatment with 30 micrograms ethinylestradiol and 75 micrograms gestodene","volume":"38","author":"Kuhl","year":"1988","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0115","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0010-7824(90)90062-Z","article-title":"Potency and pharmacokinetics of gestagens","volume":"41","author":"Fotherby","year":"1990","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0120","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/AOG.0b013e31820095a2","article-title":"Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen","volume":"117","author":"Dinger","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0125","doi-asserted-by":"crossref","first-page":"364","DOI":"10.2165\/00003495-199550020-00010","article-title":"Gestodene. A review of its pharmacology, efficacy and tolerability in combined contraceptive preparations","volume":"50","author":"Wilde","year":"1995","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.contraception.2013.12.003_bb0130","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1056\/NEJM199011153232003","article-title":"The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism","volume":"323","author":"Godsland","year":"1990","journal-title":"N Engl J Med"},{"issue":"Suppl.","key":"10.1016\/j.contraception.2013.12.003_bb0135","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/0021-9150(94)90154-6","article-title":"Lipids, lipoproteins, women and cardiovascular disease","volume":"108","author":"Miller","year":"1994","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0140","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1161\/01.ATV.0000057572.97137.DD","article-title":"Importance of different pathways of cellular cholesterol efflux","volume":"23","author":"Yancey","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0010-7824(94)90106-6","article-title":"New progestogens in oral contraception","volume":"49","author":"Fotherby","year":"1994","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0150","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00404-008-0907-x","article-title":"Effects of two combined oral contraceptives containing ethinyl estradiol 30 microg combined with either gestodene or drospirenone on hemostatic parameters, lipid profiles and blood pressure","volume":"280","author":"Yildizhan","year":"2009","journal-title":"Arch Gynecol Obstet"},{"issue":"6","key":"10.1016\/j.contraception.2013.12.003_bb0155","first-page":"1034","article-title":"Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins","volume":"81","author":"Speroff","year":"1993","journal-title":"Obstet Gynecol."},{"issue":"5 Pt 2","key":"10.1016\/j.contraception.2013.12.003_bb0160","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/S0002-9378(94)05020-9","article-title":"New progestins\u2013clinical experiences: gestodene","volume":"170","author":"Shoupe","year":"1994","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2013.12.003_bb0165","series-title":"The new option in low-dose oral contraception - expanding the gestodene choice","article-title":"The influence of a low-dose oral contraceptive containing 20mcg ethinylestradiol and 75mcg gestodene on lipid and carbohydrate metabolism","author":"Winkler","year":"1995"},{"issue":"Suppl.","key":"10.1016\/j.contraception.2013.12.003_bb0170","first-page":"29","article-title":"Clinical and metabolic effects of gestodene and levonorgestrel","volume":"32","author":"Rabe","year":"1987","journal-title":"Int J Fertil"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0175","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0010-7824(98)00074-2","article-title":"Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters","volume":"58","author":"Wiegratz","year":"1998","journal-title":"Contraception"},{"issue":"1 Pt 2","key":"10.1016\/j.contraception.2013.12.003_bb0180","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0002-9378(90)90583-S","article-title":"Time-dependent alterations in lipid metabolism during treatment with low-dose oral contraceptives","volume":"163","author":"Kuhl","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"1 Pt 2","key":"10.1016\/j.contraception.2013.12.003_bb0185","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0002-9378(90)90579-V","article-title":"Mechanism of action of oral contraceptives on carbohydrate metabolism at the cellular level","volume":"163","author":"Skouby","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0190","first-page":"64","article-title":"Insulin resistance, secretion, and metabolism in users of oral contraceptives","volume":"74","author":"Godsland","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.contraception.2013.12.003_bb0195","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0010-7824(02)00415-8","article-title":"Randomized controlled study of the influence of two low estrogen dose oral contraceptives containing gestodene or desogestrel on carbohydrate metabolism","volume":"66","author":"Ludicke","year":"2002","journal-title":"Contraception"},{"issue":"1 Pt 2","key":"10.1016\/j.contraception.2013.12.003_bb0200","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0002-9378(90)90578-U","article-title":"Clinical aspects of the relationship between oral contraceptives, abnormalities in carbohydrate metabolism, and the development of cardiovascular disease","volume":"163","author":"Gaspard","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0205","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0010-7824(94)90087-6","article-title":"Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinyl estradiol","volume":"49","author":"Spellacy","year":"1994","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0210","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2141.1988.tb07631.x","article-title":"A comparison of the effects of two triphasic oral contraceptives on haemostasis","volume":"69","author":"Cohen","year":"1988","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0215","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0010-7824(90)90036-U","article-title":"Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins","volume":"41","author":"Ball","year":"1990","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0220","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1177\/107602969900500112","article-title":"Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel","volume":"5","author":"Prasad","year":"1999","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1 Pt 2","key":"10.1016\/j.contraception.2013.12.003_bb0225","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/0002-9378(90)90585-U","article-title":"Metabolic changes during treatment with two different progestogens","volume":"163","author":"Refn","year":"1990","journal-title":"Am J Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0230","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0010-7824(95)00271-5","article-title":"A comparative study of the effects of the hemostatic system of two monophasic gestodene oral contraceptives containing 20 micrograms and 30 micrograms ethinylestradiol","volume":"53","author":"Winkler","year":"1996","journal-title":"Contraception"},{"issue":"24","key":"10.1016\/j.contraception.2013.12.003_bb0235","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMoa1111840","article-title":"Thrombotic stroke and myocardial infarction with hormonal contraception","volume":"366","author":"Lidegaard","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2013.12.003_bb0240","doi-asserted-by":"crossref","first-page":"d6423","DOI":"10.1136\/bmj.d6423","article-title":"Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001\u20139","volume":"343","author":"Lidegaard","year":"2011","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0245","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.contraception.2009.12.014","article-title":"Use of oral contraceptives containing gestodene and risk of venous thromboembolism: outlook 10years after the third-generation \"pill scare\"","volume":"81","author":"Heinemann","year":"2010","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0250","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/jfprhc-2011-100260","article-title":"Combined oral contraceptives, venous thromboembolism, and the problem of interpreting large but incomplete datasets","volume":"38","author":"Dinger","year":"2012","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"3","key":"10.1016\/j.contraception.2013.12.003_bb0255","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1783\/147118910791749416","article-title":"Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case\u2013control study","volume":"36","author":"Dinger","year":"2010","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0260","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1136\/bjsm.2005.020065","article-title":"Effect of oral contraceptives and hormone replacement therapy on bone mineral density in premenopausal and perimenopausal women: a systematic review","volume":"40","author":"Liu","year":"2006","journal-title":"Br J Sports Med"},{"issue":"3","key":"10.1016\/j.contraception.2013.12.003_bb0265","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1093\/humupd\/dmg017","article-title":"Sex steroids and bone: current perspectives","volume":"9","author":"Balasch","year":"2003","journal-title":"Hum Reprod Update"},{"issue":"4861","key":"10.1016\/j.contraception.2013.12.003_bb0270","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.3388021","article-title":"Evidence of estrogen receptors in normal human osteoblast-like cells","volume":"241","author":"Eriksen","year":"1988","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.contraception.2013.12.003_bb0275","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1073\/pnas.88.15.6613","article-title":"Avian osteoclasts as estrogen target cells","volume":"88","author":"Oursler","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0280","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/01.AOG.0000148344.26475.fc","article-title":"Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density","volume":"105","author":"Nappi","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0285","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0010-7824(00)00104-9","article-title":"Evidence that treatment with monophasic oral contraceptive formulations containing ethinylestradiol plus gestodene reduces bone resorption in young women","volume":"61","author":"Paoletti","year":"2000","journal-title":"Contraception"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0290","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0010-7824(03)00025-8","article-title":"Effects of a low-dose and ultra-low-dose combined oral contraceptive use on bone turnover and bone mineral density in young fertile women: a prospective controlled randomized study","volume":"67","author":"Nappi","year":"2003","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2013.12.003_bb0295","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.contraception.2003.11.001","article-title":"Sexual behavior of women taking low-dose oral contraceptive containing 15 microg ethinylestradiol\/60 microg gestodene","volume":"69","author":"Caruso","year":"2004","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0300","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1743-6109.2005.00198.x","article-title":"Impact of oral contraceptives on sex hormone-binding globulin and androgen levels: a retrospective study in women with sexual dysfunction","volume":"3","author":"Panzer","year":"2006","journal-title":"J Sex Med"},{"issue":"Suppl. 4","key":"10.1016\/j.contraception.2013.12.003_bb0305","first-page":"S17","article-title":"A double blind randomized control trial, comparing effect of drospirenone and gestodene to sexual desire and libido","volume":"89","author":"Oranratanaphan","year":"2006","journal-title":"J Med Assoc Thai"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0310","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2265.1980.tb02718.x","article-title":"Androgens and sexual behaviour in women using oral contraceptives","volume":"12","author":"Bancroft","year":"1980","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0315","doi-asserted-by":"crossref","first-page":"253","DOI":"10.3109\/13625189709165303","article-title":"Sex steroids and libido","volume":"2","author":"Dei","year":"1997","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0320","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/jama.294.1.91","article-title":"Circulating androgen levels and self-reported sexual function in women","volume":"294","author":"Davis","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0325","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.contraception.2013.04.001","article-title":"The creeping pearl: why has the rate of contraceptive failure increased in clinical trials of combined hormonal contraceptive pills?","volume":"88","author":"Trussell","year":"2013","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0330","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0500","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ajog.2012.04.022","article-title":"Pharmacokinetics and ovarian suppression during use of a contraceptive vaginal ring in normal-weight and obese women","volume":"207","author":"Westhoff","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.contraception.2013.12.003_bb0340","doi-asserted-by":"crossref","unstructured":"Westhoff C, Reinecke I, Bangerter K, Merz M. Impact of body mass index on suppression of follicular development and ovulation using a transdermal patch containing 0.55 mg ethinyl estradiol\/2.1 mg gestodene: a multicenter, open-label, uncontrolled study over three treatment cycles. Manuscript in preparation. 2013.","DOI":"10.1016\/j.contraception.2014.04.018"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0345","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.contraception.2011.09.019","article-title":"Predictors of noncompliance in an oral contraceptive clinical trial","volume":"85","author":"Westhoff","year":"2012","journal-title":"Contraception"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0350","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0010-7824(91)90037-G","article-title":"Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users","volume":"43","author":"Brill","year":"1991","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0355","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0010-7824(92)90128-G","article-title":"Triphasic combination of ethinyl estradiol and gestodene. Long-term clinical trial","volume":"46","author":"Weber-Diehl","year":"1992","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0360","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3109\/09513599309152510","article-title":"Efficacy, cycle control and side-effects of two monophasic combination oral contraceptives: gestodene\/ethinylestradiol and norgestimate\/ethinylestradiol","volume":"7","author":"Affinito","year":"1993","journal-title":"Gynecol Endocrinol"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0365","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0010-7824(94)90107-4","article-title":"Clinical comparison of two low-dose oral contraceptives, Minulet and Mercilon, in women over 30years of age","volume":"49","author":"Kirkman","year":"1994","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2013.12.003_bb0370","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0028-2243(90)90079-G","article-title":"A double-blind comparison of the efficacy and acceptability of Femodene and Microgynon-30","volume":"34","author":"Loudon","year":"1990","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0375","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0010-7824(93)90076-J","article-title":"Comparison of two triphasic oral contraceptives containing either gestodene or norethindrone: a randomized, controlled trial","volume":"48","author":"Weber-Diehl","year":"1993","journal-title":"Contraception"},{"issue":"3","key":"10.1016\/j.contraception.2013.12.003_bb0380","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/AOG.0b013e3182a1741c","article-title":"Norethindrone acetate 1.0 milligram and ethinyl estradiol 10 micrograms as an ultra low-dose oral contraceptive","volume":"122","author":"Archer","year":"2013","journal-title":"Obst Gynecol"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0385","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.contraception.2006.08.004","article-title":"Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1mg\/ethinyl estradiol 20 micro g (Loestrin 24 Fe)","volume":"75","author":"Nakajima","year":"2007","journal-title":"Contraception"},{"issue":"9","key":"10.1016\/j.contraception.2013.12.003_bb0390","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3109\/09513590.2011.588848","article-title":"Vascular dysfunction as a cause of endometrial bleeding","volume":"28","author":"Archer","year":"2012","journal-title":"Gynecol Endocrinol"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0395","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0010-7824(95)00270-7","article-title":"The effect of desogestrel, gestodene, and other factors on spotting and bleeding","volume":"53","author":"Rosenberg","year":"1996","journal-title":"Contraception"},{"issue":"1","key":"10.1016\/j.contraception.2013.12.003_bb0400","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/oxfordjournals.bmb.a072593","article-title":"Combined oral contraceptives: acceptability and effective use","volume":"49","author":"Kubba","year":"1993","journal-title":"Br Med Bull"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0405","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0010-7824(93)90034-5","article-title":"Effect of four combined oral contraceptives on blood pressure in the pill-free interval","volume":"47","author":"Nichols","year":"1993","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2013.12.003_bb0410","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1046\/j.1365-2125.2000.00198.x","article-title":"A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives","volume":"49","author":"Farmer","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0415","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.contraception.2006.12.018","article-title":"Range of published estimates of venous thromboembolism incidence in young women","volume":"75","author":"Heinemann","year":"2007","journal-title":"Contraception"},{"issue":"6","key":"10.1016\/j.contraception.2013.12.003_bb0420","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0010-7824(94)90099-X","article-title":"Haemostasis profile in smoking and nonsmoking women taking low-dose oral contraceptives","volume":"49","author":"Fruzzetti","year":"1994","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0425","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/humrep\/15.4.817","article-title":"Recurrent use of newer oral contraceptives and the risk of venous thromboembolism","volume":"15","author":"Suissa","year":"2000","journal-title":"Hum Reprod"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0430","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/bjc.1993.175","article-title":"Norgestrel and gestodene stimulate breast cancer cell growth through an oestrogen receptor mediated mechanism","volume":"67","author":"Catherino","year":"1993","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0435","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0960-0760(92)90257-J","article-title":"Effects of progestins on the proliferation of estrogen-dependent human breast cancer cells under growth factor-defined conditions","volume":"42","author":"van der Burg","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0440","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.contraception.2003.12.015","article-title":"Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer","volume":"69","author":"Strom","year":"2004","journal-title":"Contraception"},{"issue":"8","key":"10.1016\/j.contraception.2013.12.003_bb0445","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1158\/0008-5472.CAN-11-4064","article-title":"Effect of depo-medroxyprogesterone acetate on breast cancer risk among women 20 to 44years of age","volume":"72","author":"Li","year":"2012","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.contraception.2013.12.003_bb0450","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1258\/0007142001903337","article-title":"Health consequences of combined oral contraceptives","volume":"56","author":"Hannaford","year":"2000","journal-title":"Br Med Bull"},{"issue":"9312","key":"10.1016\/j.contraception.2013.12.003_bb0455","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(02)08150-3","article-title":"Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case\u2013control study","volume":"359","author":"Moreno","year":"2002","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.contraception.2013.12.003_bb0460","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/bjc.1995.260","article-title":"Endometrial and ovarian cancer and oral contraceptives\u2013findings in a large cohort study","volume":"71","author":"Vessey","year":"1995","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.contraception.2013.12.003_bb0465","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0960-0760(91)90129-S","article-title":"Effect of the progestogens, gestodene, 3-keto desogestrel, levonorgestrel, norethisterone and norgestimate on the oxidation of ethinyloestradiol and other substrates by human liver microsomes","volume":"38","author":"Back","year":"1991","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"5","key":"10.1016\/j.contraception.2013.12.003_bb0470","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0010-7824(97)00030-9","article-title":"Pharmacokinetics of the new progestogens and influence of gestodene and desogestrel on ethinylestradiol metabolism","volume":"55","author":"Stanczyk","year":"1997","journal-title":"Contraception"},{"issue":"4","key":"10.1016\/j.contraception.2013.12.003_bb0475","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2125.2000.00271.x","article-title":"Effect of an oral contraceptive preparation containing ethinylestradiol and gestodene on CYP3A4 activity as measured by midazolam 1\u2032-hydroxylation","volume":"50","author":"Palovaara","year":"2000","journal-title":"Br J Clin Pharmacol"},{"issue":"1A","key":"10.1016\/j.contraception.2013.12.003_bb0480","doi-asserted-by":"crossref","first-page":"116S","DOI":"10.1016\/S0002-9343(99)80069-2","article-title":"Androgenic effects of oral contraceptives: implications for patient compliance","volume":"98","author":"Jones","year":"1995","journal-title":"Am J Med"},{"key":"10.1016\/j.contraception.2013.12.003_bb0485","doi-asserted-by":"crossref","first-page":"b2890","DOI":"10.1136\/bmj.b2890","article-title":"Hormonal contraception and risk of venous thromboembolism: national follow-up study","volume":"339","author":"Lidegaard","year":"2009","journal-title":"BMJ"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782413007464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782413007464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T00:58:33Z","timestamp":1564966713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782413007464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":97,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0010782413007464"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2013.12.003","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}